{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:12:22Z","timestamp":1777878742277,"version":"3.51.4"},"reference-count":56,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["World J Pediatr Congenit Heart Surg"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>Cardiopulmonary bypass (CPB) is essential for the conduct of open-heart procedures. While lifesaving, CPB can be associated with significant end-organ injuries believed to result from inflammatory responses triggered by the extracorporeal surfaces encountering cellular elements in the blood stream. In this review, we discuss the role of interleukin-6 (IL-6) and the potential for Tocilizumab, an anti-IL-6 receptor antibody, in mitigating these effects. We compare the inflammatory responses in CPB and cytokine storm, a clinical condition in which Tocilizumab has been effectively implemented. Finally, we examine why corticosteroids, used to reduce the morbidity of CPB, may not effectively reduce IL-6 levels.<\/jats:p>","DOI":"10.1177\/21501351241285449","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T03:51:19Z","timestamp":1729828279000},"page":"395-401","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Review of Interleukin-6 and Cardiopulmonary Bypass-Related End-Organ Injury Along With the Potential for Mitigation With Tocilizumab"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4232-1340","authenticated-orcid":false,"given":"Althena","family":"Yu","sequence":"first","affiliation":[{"name":"Center for Cardiovascular Research, Division of Cardiology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junedh M.","family":"Amrute","sequence":"additional","affiliation":[{"name":"Center for Cardiovascular Research, Division of Cardiology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pirooz","family":"Eghtesady","sequence":"additional","affiliation":[{"name":"Division of Pediatric Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, Saint Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13101506"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-4975(93)91143-B"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06816-9"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2008.11.001"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc7940"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0000000000000759"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/0267659108097882"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)01503-X"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e3181f333aa"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(02)04501-0"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/1010-7940(93)90158-8"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/0267659109351218"},{"issue":"1","key":"e_1_3_3_14_2","first-page":"49","article-title":"Impact of modified ultrafiltration in congenital heart disease patients treated with cardiopulmonary bypass","volume":"1","author":"Curi-Curi PJ","year":"2018","unstructured":"Curi-Curi PJ, Alanis EA, Calder\u00f3n- Colmenero J, et al. Impact of modified ultrafiltration in congenital heart disease patients treated with cardiopulmonary bypass. Congenit Heart Dis.. 2018;1(1):49.","journal-title":"Congenit Heart Dis."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1010-7940(99)00355-3"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2004.01.030"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1051\/ject\/200638022"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212667"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.05.060"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.8133"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2014.08.042"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.10.018"},{"issue":"1","key":"e_1_3_3_23_2","first-page":"1","article-title":"Effects of systemically administered hydrocortisone on the human immunome","volume":"6","author":"Olnes MJ","year":"2016","unstructured":"Olnes MJ, Kotliarov Y, Biancotto A, et al. Effects of systemically administered hydrocortisone on the human immunome. Sci Rep. 2016;6(1):1-15.","journal-title":"Sci Rep."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23923-1"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.04.009"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0639-8"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-59815-9_24"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1906637"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.2016005"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"issue":"4","key":"e_1_3_3_32_2","first-page":"851","article-title":"Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell Growth1","volume":"53","author":"Sato K","year":"1993","unstructured":"Sato K, Tsuchiya M, Saldanha J, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell Growth1. Cancer Res. 1993;53(4):851-856. http:\/\/aacrjournals.org\/cancerres\/article-pdf\/53\/4\/851\/2452768\/cr0530040851.pdf. Accessed June 16, 2024.","journal-title":"Cancer Res"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028415"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00103-X"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.8"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0502257102"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/324073a0"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.4.1241.1241"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1177\/0885066610384188"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1051\/ject\/200537272"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-199801000-00006"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1631560"},{"key":"e_1_3_3_43_2","first-page":"349","article-title":"Tocilizumab in the treatment of rheumatoid arthritis and beyond","volume":"8","author":"Shetty A","year":"2014","unstructured":"Shetty A, Hanson R, Korsten P, et al. Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des Devel Ther. 2014;8:349-364.","journal-title":"Drug Des Devel Ther"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X12455960"},{"issue":"2","key":"e_1_3_3_45_2","article-title":"Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients","volume":"4","author":"Regola F","year":"2020","unstructured":"Regola F, Cerudelli E, Bosio G, et al. Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients. Rheumatol Adv Pract. 2020;4(2):rkaa017. doi: https:\/\/doi.org\/10.1093\/rap\/rkaa017","journal-title":"Rheumatol Adv Pract"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-018-0102-x"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.053318"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-021-00560-1"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0000000000001707"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202103-0714OC"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_3_3_52_2","unstructured":"Tocilizumab (Actemra): Adult Patients with Moderately to Severely Active Rheumatoid Arthritis [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug. Table 1 Cost-Comparison Table for Biologic Disease-Modifying Drugs for Rheumatoid Arthritis. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK349513\/table\/T43\/Accessed 10\/13\/2024"},{"key":"e_1_3_3_53_2","unstructured":"Preuss CV Anjum F. Tocilizumab. [Updated 2024 Feb 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK570644\/. Accessed 10\/13\/2024."},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2022.22028"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.08.330"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.4103\/jgid.jgid_358_20"},{"key":"e_1_3_3_57_2","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Tocilizumab. [Updated 2021 May 11]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548243\/A. Accessed 10\/13\/2024."}],"container-title":["World Journal for Pediatric and Congenital Heart Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21501351241285449","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/21501351241285449","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21501351241285449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:26:58Z","timestamp":1777591618000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/21501351241285449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1177\/21501351241285449"],"URL":"https:\/\/doi.org\/10.1177\/21501351241285449","relation":{},"ISSN":["2150-1351","2150-136X"],"issn-type":[{"value":"2150-1351","type":"print"},{"value":"2150-136X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]}}}